ITMCTR2200005783
Not yet recruiting
Phase 1
A randomized, comparison pharmacokinetic study of Jianpi Qushi Recipe and Febuxostat in Chinese hyperuricemia patients
Department of Immunity,the Tianjin FirstHospital,Tianjin,0 sitesTBD
Conditionshyperuricemia patients
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- hyperuricemia patients
- Sponsor
- Department of Immunity,the Tianjin FirstHospital,Tianjin,
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The standard age was 18\-65 years old, with no gender limitation.The inclusion criteria met the diagnostic criteria set by Multidisciplinary Expert Consensus on diagnosis and Treatment of Hyperuricemia Related Diseases in China (2017\) : for both men and women, fasting uric acid level exceeded 420µmol/L, which was called hyperuricemia.
Exclusion Criteria
- •Secondary gout caused by kidney disease, blood disease, taking drugs, tumor radiation and chemotherapy, etc. In the acute onset of gouty arthritis; Caused by rheumatoid arthritis, psoriatic arthritis, bone tumors and other joint lesions; With serious pulmonary, cardiovascular, hematopoietic, central nervous system or other systemic diseases; Complicated with malignant tumor; Glutamic\-pyruvic transaminase or glutamic\-oxalacetic transaminase was 1\.5 times higher than the upper limit of normal range; Serum creatinine was higher than the upper limit of normal range; Had undergone sex hormone replacement therapy and oral contraception in the past 3 months; Taking more than 10 mg/d of prednisone or other equivalent glucocorticoids; Or failing to take medication as prescribed. Pregnant or breast\-feeding women or those who plan to become pregnant; Allergic to test drugs, weak physique or allergic constitution: those who meet any one of the above criteria can be excluded from the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A research study of how fast-acting insulin aspart works in the body of children, young people and grown-ups with type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 20.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2017-002014-31-DEovo Nordisk A/S43
Active, not recruiting
Phase 1
A Randomized Double-blind study of Ustekinumab in Pediatric Subjects with Crohn's DiseaseModerately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2016-001956-22-PLJanssen-Cilag International N.V.40
Active, not recruiting
Phase 1
A Randomized Double-blind study of Ustekinumab in Pediatric Subjects with Crohn's DiseaseEUCTR2016-001956-22-DEJanssen-Cilag International N.V.40
Active, not recruiting
Phase 1
A Randomized Double-blind study of Ustekinumab in Pediatric Subjects with Crohn's DiseaseModerately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2016-001956-22-BEJanssen-Cilag International N.V.40
Active, not recruiting
Phase 1
A Randomized Double-blind study of Ustekinumab in Pediatric Subjects with Crohn's DiseaseModerately to severely active Crohn's diseaseMedDRA version: 19.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2016-001956-22-FRJanssen-Cilag International N.V.40